IDIOPATHIC PULMONARY FIBROSIS · IPF · NON-SPECIFIC INTERSTITIAL PNEUMONIA
A physician-led, laboratory-verified treatment programme designed to slow fibrotic progression, stabilise lung function and improve exercise tolerance — tailored to the individual biology, disease stage and clinical profile of each pulmonary fibrosis patient.
Request Medical ConsultationAbout the Condition
Pulmonary fibrosis is a chronic, progressive lung disease characterised by excessive scarring (fibrosis) of the lung tissue. As scar tissue accumulates, the lungs become stiff and thickened, making it increasingly difficult for oxygen to pass into the bloodstream.
The condition leads to progressive breathlessness, declining exercise capacity, chronic dry cough and — in advanced stages — respiratory failure requiring supplemental oxygen. Idiopathic Pulmonary Fibrosis (IPF), the most common and aggressive form, carries a median survival of 3–5 years from diagnosis without intervention.
IPF affects approximately 13–20 people per 100,000 annually. Current approved medications (pirfenidone, nintedanib) slow the rate of FVC decline but do not halt or reverse fibrosis. Lung transplantation remains the only option with proven long-term survival benefit — but fewer than 5% of patients are eligible. Our programme targets the biological mechanisms driving fibrotic progression where conventional treatment reaches its limits.
Idiopathic Pulmonary Fibrosis (IPF)
The most common form of progressive fibrosing interstitial lung disease. Occurs without identifiable cause. Predominantly affects males over 60. Carries the worst prognosis among fibrotic lung diseases, with a median survival of 3–5 years. Characterised by a UIP (usual interstitial pneumonia) pattern on HRCT.
Non-Specific Interstitial Pneumonia (NSIP)
The second most common idiopathic interstitial pneumonia. More uniform fibrotic pattern than IPF. More responsive to immunosuppressive therapy and carries a significantly better prognosis. Often associated with autoimmune conditions. Cellular NSIP subtype generally responds better than fibrotic NSIP.
Connective Tissue Disease-associated ILD
Pulmonary fibrosis occurring in patients with systemic autoimmune conditions — rheumatoid arthritis, systemic sclerosis, dermatomyositis, Sjögren's syndrome. The autoimmune component drives both inflammation and fibrosis in the lung. Treatment must address both the pulmonary and systemic disease simultaneously.
Chronic Hypersensitivity Pneumonitis (fibrotic)
Fibrotic lung disease triggered by chronic inhalation of organic antigens — mould, bird proteins, chemical exposures. Once fibrosis is established, the disease may progress independently of antigen exposure. Diagnosis often delayed due to overlap with IPF on imaging. Requires removal of the causative antigen where identifiable.
Our program is individually adapted for all subtypes and all stages of progression.
Important: Each patient is accepted into the programme only after a comprehensive individual medical assessment, which evaluates diagnosis, disease stage, pulmonary function parameters, oxygen requirements and overall clinical profile.
We do not offer a cure for pulmonary fibrosis. Our programme is designed to target the biological mechanisms driving fibrotic progression — with the clinical objective of stabilising lung function, slowing decline and improving daily exercise tolerance and quality of life.
Clinical Outcomes
The following data are derived from structured observational analysis of patients treated at BioCells Medical between 2017 and 2025. All figures represent aggregated clinical registry outcomes with longitudinal follow-up. These are observational results — not randomised controlled trial data — and do not constitute a guarantee of therapeutic effect.
28
pulmonary fibrosis patients treated
68%
demonstrated measurable stabilisation of FVC within 3–6 months
57%
showed improvement in 6-minute walk test distance
61%
reported reduced supplemental oxygen requirement or stable oxygen levels
+4.2%
average FVC change (% predicted) in the first 6 months
64%
maintained sustained functional stability — follow-up to 2 years
Improved 6-minute walk test distance
57%
Stabilised or improved FVC (% predicted)
68%
Reduced supplemental oxygen dependency
46%
Decreased frequency and severity of chronic cough
54%
Improved DLCO (diffusing capacity for carbon monoxide)
39%
3–8 weeks
Initial functional response
3–6 months
Clinically meaningful change
1–2 years under continued monitoring
Functional stabilisation phase
Important: Outcomes depend on fibrosis subtype, baseline FVC and DLCO values, disease duration, oxygen requirements and individual biological response. Individual results may vary significantly.
Find out if our program can help in your specific case. The initial medical consultation is free and carries no obligation.
Request ConsultationPatient Stories
“My lung function had been dropping steadily for two years. Medication slowed it but could not stop it. After treatment, my pulmonologist measured an improvement for the first time. I can walk to the end of my street again without portable oxygen. That matters more than any number on a chart.”
Patient
IPF · Italy
Every case is assessed individually by our physician team. Request a consultation to discuss your specific situation with our physician team.
Request ConsultationThe BioCells Program
Our pulmonary fibrosis programme combines five biological components into a single personalised protocol. No two protocols are identical — each is constructed following a detailed medical evaluation of the patient's biological profile, disease stage and clinical priorities.
No surgery required
Treatment is delivered by intravenous infusion — not surgical instruments. No thoracic procedure, no intubation.
No general anaesthesia
Particularly important in pulmonary fibrosis, where compromised respiratory function may make general anaesthesia high-risk.
No risk of immune rejection — autologous option
Where clinically appropriate, we use the patient's own cells. Zero risk of graft-versus-host disease with autologous protocols.
Targets fibrotic biology, not just symptoms
Rather than masking breathlessness, our protocol targets myofibroblast activation, TGF-β signalling and alveolar epithelial damage — the biological drivers of fibrotic progression.
Complements existing antifibrotic medication
Our programme is compatible with pirfenidone, nintedanib and other current standard medications. Patients do not need to discontinue existing treatment before commencing our protocol.
Treatment at your location worldwide
Our medical team is available to conduct treatment at our Warsaw clinic or to travel to the patient's location anywhere in the world. For patients with advanced pulmonary fibrosis where long-distance travel and pressurised cabin environments pose clinical risk, this removes a major barrier to accessing care.
What It Is
MSCs are multipotent regenerative cells with proven antifibrotic, anti-inflammatory and immunomodulatory properties. They are among the most extensively studied cell types in regenerative medicine and have demonstrated safety across thousands of clinical applications worldwide.
How It Is Done
Cells are collected from the patient's own bone marrow (autologous, approximately 50 ml under local anaesthesia) or sourced from a certified donor (allogeneic), depending on individual clinical indications. All cells are then expanded, quality-controlled and tested in our certified Warsaw laboratory before administration.
Biological Mechanisms
How This Helps in Pulmonary Fibrosis
In pulmonary fibrosis, repeated alveolar epithelial injury triggers an aberrant wound-healing response dominated by myofibroblast proliferation and excessive extracellular matrix deposition. MSCs directly address this mechanism by suppressing myofibroblast differentiation, reducing epithelial apoptosis and creating conditions that favour tissue repair over continued scarring.
Your Medical Board
The exact combination, dosage, sequencing and delivery method of all five components is determined individually by our medical board for each patient. No two treatment protocols are identical. Your programme is constructed based on your specific diagnosis, disease stage, biological markers and clinical priorities.
Your protocol is designed individually. Speak with our medical team to understand what your personalised program would include.
Request ConsultationPatient Journey
Your case is reviewed remotely by our physician team. We assess your diagnosis, current FVC and DLCO values, oxygen requirements, medical history and treatment goals. This consultation is free and carries no obligation.
A detailed review of all medical documentation including HRCT imaging, pulmonary function tests and blood work. Our medical board evaluates eligibility, confirms safety parameters and designs your personalised therapeutic protocol.
Your cells are collected, isolated, expanded and quality-tested in our certified Warsaw laboratory. Each batch receives a full traceability certificate. This stage typically takes 2–3 weeks.
Cells are delivered by intravenous infusion — no surgery, no general anaesthesia. Treatment is available at our Warsaw clinic or with our medical team at your location worldwide. Airport transfers, accommodation and visa support are included in the programme. Where clinically appropriate, our medical board may approve a travelling treatment programme — our medical team flies directly to the patient.
Structured respiratory rehabilitation sessions with our specialist, adapted to your current pulmonary function and exercise capacity. Available at our clinic or remotely coordinated with your local pulmonary rehabilitation team.
Your dedicated coordinator monitors pulmonary function status, provides clinical guidance and adjusts recommendations based on your recovery data. A medical-grade wearable bracelet supports continuous oxygen saturation and activity tracking regardless of your location.
The first step is free. Request a medical consultation and our medical consultant will contact you within 24 hours.
Request ConsultationSafety Profile
Cellular therapy is considered safe when delivered under proper medical supervision and according to validated protocols. In our practice, the procedure is well-tolerated by the majority of pulmonary fibrosis patients.
Temporary mild reactions — such as transient low-grade fever, slight fatigue or mild cough exacerbation in the first 24–48 hours — may occur in a minority of patients. These are typically short-lived and indicate active immune engagement.
A final medical assessment is performed on-site before every treatment session. If a patient's status has changed — including acute respiratory exacerbation or significant oxygen desaturation — the programme may be temporarily modified or postponed for safety reasons.
All contraindications are evaluated individually. A contraindication in one clinical context does not necessarily preclude treatment in a different context — this is always determined by physician assessment.
Standard Contraindications
Active acute respiratory infection or pneumonia
Active malignancy or ongoing chemotherapy / radiotherapy
Severe decompensated cardiac or renal failure
Severe pulmonary hypertension with right heart failure (assessed individually)
Pregnancy
Post-Treatment
Dedicated respiratory specialist
monitors pulmonary function, oxygen saturation trends and overall clinical trajectory
Personalised respiratory rehabilitation programme
adapted to current FVC, exercise capacity and oxygen requirements
Medical-grade wearable monitoring
continuous SpO2 and activity data collection supporting clinical decision-making
Long-term coordinator support
proactive check-ins, clinical guidance and response to any changes in pulmonary status
Continued clinical access
our medical team remains available for ongoing reassessment and protocol adjustment
Fibrotic lung tissue remodelling is a gradual biological process. The weeks and months following treatment require structured monitoring, respiratory rehabilitation and clinical oversight. We maintain active follow-up for as long as it remains clinically relevant — there is no arbitrary cut-off point.
Get Started
If you or someone you love has been diagnosed with pulmonary fibrosis, our medical team is available for a free, no-obligation medical consultation — based on your diagnosis, current pulmonary function and individual clinical profile.
We review every inquiry personally. You will speak with a physician, not an administrator.
Submit your case online or by phone
Our medical consultant contacts you to review your documents
The medical board presents your personalised treatment plan
Request a Consultation
Tell us about your condition. Our medical consultant will contact you within 24 hours to review your documents.
Open Consultation FormMultilingual coordination — English, Italian, French, Russian, Polish
Evidence Base
Our clinical approach is informed by and consistent with published research in the field of regenerative medicine.
